Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies

Article Ophthalmology

Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD

Ramin Khoramnia et al.

Summary: Brolucizumab may lead to IOI preceding RV or RO in some patients, with potentially significant implications for treatment strategies and patient monitoring.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2022)

添加到收藏夹

Article Ophthalmology

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study

Louisa Maria Bulirsch et al.

Summary: Switch to brolucizumab may be a viable treatment option for nAMD patients who are poorly responsive to other anti-VEGF agents, as indicated by the SHIFT study results. However, further long-term analyses are necessary to assess the efficacy and safety of brolucizumab in a routine clinical setting.

BRITISH JOURNAL OF OPHTHALMOLOGY (2022)

添加到收藏夹

Article Ophthalmology

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration Results From the IRIS Registry and Komodo Healthcare Map

Arshad M. Khanani et al.

Summary: A study on patients with neovascular age-related macular degeneration treated with brolucizumab found that the incidence rate of intraocular inflammation and/or retinal vascular occlusion was approximately 2.4%. Patients with a history of these events in the 12 months prior to the first brolucizumab injection had the highest observed risk rate for these events in the early months following treatment.

JAMA OPHTHALMOLOGY (2022)

添加到收藏夹

Editorial Material Ophthalmology

Risk Factors for Intraocular Inflammation After Brolucizumab Treatment Comment

Caroline R. Baumal

JAMA OPHTHALMOLOGY (2022)

添加到收藏夹

Review Ophthalmology

The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice

Ian Pearce et al.

Summary: Untreated neovascular age-related macular degeneration can lead to severe and permanent visual impairment, highlighting the importance of introducing new treatment options. Expert roundtable meetings provide practical guidance to support the introduction of new anti-VEGF therapy in medical retina services to meet the growing demand for care.

EYE (2022)

添加到收藏夹

Article Ophthalmology

Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration

Marius Book et al.

Summary: After switching to brolucizumab treatment, there was a significant reduction in retinal fluid among patients with refractory nAMD, although visual acuity did not improve. Future studies should continue to investigate the effects of brolucizumab in this patient population.

OPHTHALMOLOGE (2022)

添加到收藏夹

Article Ophthalmology

MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid

Arshad M. Khanani et al.

Summary: The 52-week efficacy and safety of brolucizumab and aflibercept in the treatment of neovascular age-related macular degeneration (nAMD) were compared. The study showed that brolucizumab was noninferior to aflibercept in terms of visual acuity improvement and reduction of retinal fluid, but had a higher incidence of intraocular inflammation.

OPHTHALMOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration

Alaa Din Abdin et al.

Summary: The study aimed to evaluate the morphological and functional outcomes of intravitreal brolucizumab treatment for refractory neovascular age-related macular degeneration (nAMD) in the first year. Results showed that brolucizumab could stabilize visual acuity and reduce the number of injections. It also improved anatomical outcomes by reducing subretinal fluid and pigment epithelial detachment. However, adverse events such as intraocular inflammation were observed.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Ophthalmology

Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER

Michael Singer et al.

Summary: This post hoc analysis of the HAWK and HARRIER trials provides insights into the timing, management, and outcomes of intraocular inflammation (IOI)-related adverse events (AEs) in patients receiving brolucizumab. The findings emphasize the importance of vigilance and monitoring for IOI-related events in these patients.

OPHTHALMOLOGY RETINA (2022)

添加到收藏夹

Editorial Material Ophthalmology

Brolucizumab-early real-world experience: BREW study

Ashish Sharma et al.

EYE (2021)

添加到收藏夹

Article Ophthalmology

Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study

Debdulal Chakraborty et al.

Summary: Intravitreal brolucizumab injection showed significant short-term efficacy and safety in Indian eyes with neovascular age-related macular degeneration (nAMD), leading to improved visual acuity and reduced central subfield thickness with minimal ocular adverse effects observed. Further long-term studies are needed to confirm these findings and explore the role of race and genetics in brolucizumab-related intraocular inflammations.

CLINICAL OPHTHALMOLOGY (2021)

添加到收藏夹

Review Ophthalmology

Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration

Ramin Tadayoni et al.

Summary: This article reviews the unique molecular design of brolucizumab, a single-chain antibody fragment specifically designed for intraocular use, which allows for a higher concentration of material per intravitreal injection compared to other anti-VEGF agents. Clinical trials have shown the efficacy of brolucizumab in treating nAMD, with signals of a more durable treatment effect and the ability to be administered every 3 months to maintain disease control. The preclinical and clinical data provide evidence of sustained disease control with longer injection intervals, potentially reducing the treatment burden in nAMD patients.

OPHTHALMOLOGICA (2021)

添加到收藏夹

Article Ophthalmology

Intraocular inflammation with brolucizumab use Patient management-diagnosis-therapy

F. G. Holz et al.

Summary: Brolucizumab, an anti-VEGF agent, has been approved for neovascular age-related macular degeneration in the USA and Europe. Its approval was based on phase III studies with 1817 patients, showing non-inferior efficacy compared to aflibercept. However, there have been rare adverse events such as retinal vasculitis and/or retinal vascular occlusion reported following its use.

OPHTHALMOLOGE (2021)

添加到收藏夹

Review Ophthalmology

A Global Assessment of Eye Health and Quality of Life A Systematic Review of Systematic Reviews

Lama Assi et al.

Summary: There is a significant association between vision impairment or eye diseases and reduced quality of life, and ophthalmic interventions have been shown to improve quality of life.

JAMA OPHTHALMOLOGY (2021)

添加到收藏夹

Article Ophthalmology

Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration

Ana Bety Enriquez et al.

Summary: In this analysis of brolucizumab intravitreal injection for neovascular age-related macular degeneration, visual acuity remained stable with a reduction in central subfield thickness. Intraocular inflammation events ranged from mild and self-limited to severe occlusive retinal vasculitis in one eye.

JAMA OPHTHALMOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice

Andrea Montesel et al.

Summary: This study reports the early efficacy and safety outcomes of treating nAMD with intravitreal injections of brolucizumab. The results showed that brolucizumab was highly effective in restoring anatomy and stabilizing visual acuity, but its safety profile requires further evaluation.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Review Ophthalmology

Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations

Laurent Kodjikian et al.

Summary: Current guidelines on the management of neovascular age-related macular degeneration (nAMD) do not provide clear recommendations on the interpretation of fluid seen on optical coherence tomography (OCT) imaging. This study reviewed current guidelines and evidence on the role of fluid as a biomarker in nAMD management, developing a clinically oriented algorithm based on expert consensus. The findings emphasize the importance of fluid as a critical biomarker for disease activity in nAMD diagnosis and management.

EYE (2021)

添加到收藏夹

Letter Ophthalmology

Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study

Ichiro Maruko et al.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy

Hidetaka Matsumoto et al.

Summary: Loading phase treatment with intravitreal brolucizumab may improve visual acuity and reduce exudative changes in eyes with nAMD associated with type 1 CNV, but careful monitoring for brolucizumab-related intraocular inflammation is necessary.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Ophthalmology

Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agents at a Tertiary Referral Center

Daniela P. Reyes-Capo et al.

Summary: The incidence of infectious endophthalmitis after intravitreal anti-VEGF injections remains low between 2018 and 2020, similar to prior reports.

OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2021)

添加到收藏夹

Article Medicine, General & Internal

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes

Christof Haensli et al.

Summary: The study aimed to evaluate the effect of switching treatment to brolucizumab in eyes with neovascular age-related macular degeneration with treatment intervals of <= 6 weeks. Results showed improvement in visual performance and longer treatment intervals over 6 months, indicating the potential of brolucizumab to reduce treatment burden in nAMD, despite encountering two cases of intraocular inflammation.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study

Alper Bilgic et al.

Summary: The study aimed to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration in real-world settings. Results showed good anatomical and functional responses to the treatment, with two significant untoward events noted.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study

Alper Bilgic et al.

Summary: The study demonstrates that PRN brolucizumab therapy without a loading dose shows significant efficacy in improving visual acuity for neovascular AMD patients, with no adverse events observed.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Ophthalmology

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments

Rehan M. Hussain et al.

Summary: The study found that switching to IVBr in nAMD eyes with persistent IRF/SRF significantly reduced fluid retention, but did not significantly impact visual outcomes.

THERAPEUTIC ADVANCES IN OPHTHALMOLOGY (2021)

添加到收藏夹

Article Ophthalmology

Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment

Caroline R. Baumal et al.

Summary: This study presents clinical presentations and management recommendations for ocular inflammatory events in neovascular age-related macular degeneration (nAMD) patients treated with brolucizumab. Recommendations include thorough ocular examinations and imaging modalities, prompt cessation of treatment and intensive therapy if diagnosed with inflammatory events, and consideration of individualized locally available standard of care based on clinical outcomes.

OPHTHALMOLOGY RETINA (2021)

添加到收藏夹

Article Ophthalmology

Brolucizumab-Associated Intraocular Inflammation in Eyes Without Retinal Vasculitis

Andre J. Witkin et al.

Summary: This study examines eyes with brolucizumab-associated intraocular inflammation, finding that symptoms typically appear a few weeks after injection, with most symptoms being mild and resolving, but a small percentage of patients experiencing significant vision loss at last follow-up.

JOURNAL OF VITREORETINAL DISEASES (2021)

添加到收藏夹

Article Ophthalmology

Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injections

Cynthia K. McClard et al.

Summary: Through the study, it was found that the burden of repeated IVI treatment for patients mainly manifests in the disruption of normal routine or capacity, anxiety, frequency of visits, chronicity of disease, and perceived treatment value or satisfaction. Understanding and quantifying this burden can help improve treatment methods, maximize treatment adherence, and optimize patient experiences.

BMJ OPEN OPHTHALMOLOGY (2021)

添加到收藏夹

Article Ophthalmology